with Detailed Rationales
Course Code: HS 3310
Course Name: NIOSH Approved Spirometry Training
Topic: Pulmonary Function Testing, Calibration, Quality Assurance, and Curve
Maneuver Acceptability
Academic Year: 2026/2027
Question 1
,According to the NIOSH and ATS/ERS standards, what is the maximum
allowable volume error when performing a daily verification check using a 3-Liter
calibration syringe?
A) ±0.5% or ±0.015 Liters
B) ±1.0% or ±0.030 Liters
C) ±3.0% or ±0.090 Liters
D) ±5.0% or ±0.150 Liters
CORRECT ANSWER: C) ±3.0% or ±0.090 Liters
RATIONALE: The American Thoracic Society (ATS) and NIOSH mandate
that the daily calibration check of a spirometer using a standard 3-Liter syringe
must yield a measured volume within ±3% of the target, which equates to an
absolute limit between 2.910 L and 3.090 L (error of ±0.090 L). Choice A and B
are too strict for mechanical field limits, while Choice D represents acceptable
clinical variability for a patient's effort, not equipment calibration.
Question 2
When evaluating a volume-time curve for maneuver acceptability, what is the
required End-of-Test (EOT) plateau criterion for an adult patient?
A) The patient must exhale for at least 3 seconds without any cessation of airflow.
B) The volume change is less than 0.025 Liters for a minimum of 1 full second.
C) The expiratory flow rate drops below 0.500 Liters per second for at least 2
consecutive seconds.
D) The total accumulation of volume reaches an absolute plateau matching the
predicted FVC value.
CORRECT ANSWER: B) The volume change is less than 0.025 Liters for a
minimum of 1 full second.
RATIONALE: To guarantee a complete Forced Vital Capacity (FVC) effort,
the ATS/ERS guidelines define a stable volume-time plateau as a change in
volume of <0.025 L (25 mL) for at least 1.0 second. Choice A is incorrect
because the minimum duration is 6 seconds for adults, though the plateau must still
be achieved. Choice C and D use arbitrary or incorrect numerical metrics that do
not define standard EOT criteria.
,Question 3
An technician observes a patient's flow-volume loop and notes a back-
extrapolated volume (Vext) that exceeds the acceptable threshold. What does a
high Vext mathematically signify?
A) An inadequate total expiratory time resulting in an underestimated FVC.
B) A hesitant, slow, or false start at the very beginning of the forced exhalation
maneuver.
C) Severe upper airway obstruction that limits the peak expiratory flow rate.
D) Poor effort at the tail end of the maneuver, leading to a restricted vital capacity.
CORRECT ANSWER: B) A hesitant, slow, or false start at the very
beginning of the forced exhalation maneuver.
RATIONALE: The back-extrapolated volume (Vext) measures the volume of
air lost due to a sluggish or hesitant start before the true maximum effort occurs.
Under current standards, Vext must be ≤5% of the FVC or ≤0.100 Liters
(whichever is greater) for the trial to be considered acceptable. If it exceeds this,
, the trial must be rejected. Choices A, C, and D describe terminal performance or
pathological conditions rather than initial blast errors.
Question 4
Which of the following lung parameters cannot be measured directly by standard
office spirometry testing equipment?
A) Forced Expiratory Volume in 1 Second (FEV1)
B) Peak Expiratory Flow (PEF)
C) Residual Volume (RV)
D) Forced Expiratory Flow between 25% and 75% of FVC (FEF25-75)
CORRECT ANSWER: C) Residual Volume (RV)
RATIONALE: Spirometry measures the volume of air that can be forcefully
moved into and out of the lungs. It cannot measure the Residual Volume (RV)—
the air remaining in the lungs after a maximal exhalation—nor any capacity that
contains it, such as Total Lung Capacity (TLC) or Functional Residual Capacity
(FRC). Measuring RV requires advanced body plethysmography or gas dilution
tests. Choices A, B, and D are all dynamic, flow-dependent parameters calculated
directly from an FVC maneuver.
Question 5
When performing a clinical assessment, what constitutes a statistically significant
and positive bronchodilator responsiveness test result in adults?
A) An absolute increase in FVC of at least 100 mL and 5% compared to baseline.
B) An improvement in FEV1 or FVC of ≥12% and ≥200 mL relative to the pre-
bronchodilator baseline.
C) A reduction in the FEF25-75 parameter by more than 15% following beta-
agonist administration.
D) A normalization of the FEV1/FVC ratio to an absolute value above 0.85 within
5 minutes.
CORRECT ANSWER: B) An improvement in FEV1 or FVC of ≥12% and
≥200 mL relative to the pre-bronchodilator baseline.